Rectal Cancer Clinical Trial
Official title:
Effect of Ligation Sequence of the Inferior Mesenteric Artery and Vein on Circulating Tumor Cells and Survival in Laparoscopic Rectal Cancer Surgery: a Prospective, Multicenter, Randomized Controlled Study (ARVECTS)
Effect of ligation sequence of the inferior mesenteric artery and vein on circulating tumor cells and survival in laparoscopic rectal cancer surgery: a prospective, multicenter, randomized controlled study (ARVECTS)
Status | Not yet recruiting |
Enrollment | 268 |
Est. completion date | December 2028 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Age: 18-75 years; 2. Histopathologically confirmed as rectal adenocarcinoma(tumor located within 15 cm from the anal verge at colonoscopy); 3. Patients with a stage I-III rectal cancer eligible for surgery and R0 resection is expected, patients with pelvic lateral lymph nodes metastasis are ineligible; 4. ECOG score: 0-1; 5. ASA score: I/II/III; 6. Laparoscopic surgery; 7. Informed consent. Exclusion Criteria: 1. Patients who have received preoperative treatment (such as preoperative radiotherapy and chemotherapy); 2. Receiving transanal total mesorectal excision (taTME), specimen extraction through natural lumen (NOSES) ; 3. Recurrent rectal cancer; 4. Simultaneous or metachronous colorectal cancer; 5. Malignant tumors of other organs in the past 5 years or at the same time; 6. The results of preoperative physical examination and imaging examination showed that: (1) the tumor involved the surrounding organs and required combined organ resection; (2) distant metastasis; (3) could not be resected at R0; 7. Pregnant or lactating women; 8. Patients with severe mental disorder; 9. It is not suitable for patients undergoing laparoscopic surgery (such as extensive adhesion caused by previous abdominal surgery or inability to tolerate artificial pneumoperitoneum); 10. History of unstable angina pectoris or myocardial infarction in the past 6 months; 11. Have a history of cerebrovascular accident in the past 6 months; 12. Systemic administration of corticosteroids within 1 month before enrollment; 13. Taking folic acid related drugs within half a year before operation. 14. Severe cardiac insufficiency (FEV1<50% of predicted values); 15. Emergency surgery. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sichuan Cancer Hospital and Research Institute | Sichuan Provincial People's Hospital, The Second People's Hospital of Chengdu |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The changes of the level of circulating tumor cells in the peripheral blood | The changes of the level of circulating tumor cells in the peripheral blood before cutting the skin and after closing the abdomen | During the surgery | |
Secondary | 3-year disease-free survival | The proportion of patients with no disease recurrence and metastasis after 3 years of surgery | From date of surgery, assessed up to 36 months | |
Secondary | 3-years overall survival | The proportion of patients who survived 3 years after surgery | From date of surgery, assessed up to 36 months | |
Secondary | Recurrence pattern | Recurrence patterns are classified into five categories at the time of first diagnosis: locoregional, hematogenous, peritoneal, distant lymph node, and mixed type | From date of surgery, assessed up to 36 months | |
Secondary | Blood loss | Blood loss during the surgery | During the surgery | |
Secondary | Operation time | Operation time | During the surgery | |
Secondary | Conversive rate | Conversive rate | During the surgery | |
Secondary | Number of lymph nodes collected | Number of lymph nodes collected | During the surgery | |
Secondary | Intraoperative morbidity and mortality rates | The intraoperative morbidity rates are defined as the rates of event observed within operation | During the surgery | |
Secondary | Postoperative morbidity and motality rates | This is for the early postoperative complication, which defined as the event observed within 30 days after surgery | 30 days | |
Secondary | Postoperative recovery course | Time to first ambulation, flatus, liquid diet and soft diet, duration of postoperative hospital stay and postoperative pain are used to assess the postoperative recovery course.Visual analog pain score method is used to evaluate the difference of postoperative pain degree | 10 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 |